Diabetes Drug Delivery Devices Market Overview
The global diabetes drug delivery devices market, valued at USD 17 billion in 2025, is projected to reach USD 18 billion in 2026 and USD 31 billion by 2030, with a 14.1% CAGR during the forecast period 2026 to 2030.
To learn more about this report, request a free sample copy
Diabetes is considered to be among the seventh leading causes of mortality worldwide. The chronic and debilitating nature of the condition has a severe impact on the quality of life of patients. According to the World Health Organization (WHO), more than 400 million individuals across the world are currently suffering from diabetes; this number is estimated to reach over 570 million by 2030.
Insulin injection and non-insulin therapies are considered to be the primary treatment options for diabetes management. In addition, a number of innovative drugs / therapies for the treatment and management of diabetes have been developed; these are gradually being introduced into the market. It is worth mentioning that insulin, one of primary therapeutic solutions prescribed for treating diabetes, and a few other medications, require parenteral administration.
Diabetes Drug Delivery Devices Market: Key Insights
Market Drivers: Growing Incidence of Diabetes Worldwide and Role of Delivery Devices to Improve Compliance
In patients with diabetes, glycemic control is required multiple times in a day, the frequency of administration of such drugs is high (3-4 times a day).There are multiple concerns surrounding parenteral drug delivery, such as chances of dosing-related errors, risk of microbial contamination and needlestick injuries.
Since insulin and other such diabetes medications are usually self-administered, the aforementioned concerns are compounded, given that most patients lack the required medical training and / or are not cautious while self-medicating. As a result, there is a stigma associated with the risks of self-medication, which, in turn, has an impact on the patients’ drug adherence to prescribed regimens. Overall, the therapeutic efficacy is compromised, and patients fail to benefit from the recommended intervention.
Market Trends: Technologically Advanced Devices for Insulin Delivery
Over the past few years, a number of companies have developed advanced drug delivery solutions, such as insulin pumps, pen injectors / autoinjectors, jet injectors, intranasal drug delivery solutions and microneedle-based patches, in order to address the aforementioned challenges. Device developers have also come up with connected devices, which allow easy tracking of the dosage and on time delivery. On such example is Medtronic’s smart insulin pen, InPen.
In addition, the stakeholders are actively focusing on introducing innovative features, such as the development of integrated continuous glucose monitoring (CGM) system (also known as artificial pancreas) with insulin pumps, artificial intelligence algorithms, visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in diabetes drug delivery devices industry during the forecast period.
Key Companies in Diabetes Drug Delivery Devices Market
Examples of key companies engaged in diabetes drug delivery devices market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bigfoot Biomedical, Debiotech, Haselmeier, Medtronic, Novo Nordisk, Roche, SOOIL, and Ypsomed. This market report includes an easily searchable excel database of all the companies providing diabetes drug delivery devices, worldwide.
Recent Developments in Diabetes Drug Delivery Devices Market:
Several recent developments have taken place in the field of diabetes drug delivery devices market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In May 2026, ViCentra announced the commercial launch of its smartphone-controlled Kaleido hybrid closed-loop insulin delivery patch pump system, integrating Diabeloop’s DBLG2 algorithm and the Dexcom G7 CGM.
- In May 2026, Insulet initiated its EVOLVE pivotal trial for a fully closed-loop automated insulin delivery system targeting type 2 diabetes. The randomized controlled study evaluated safety and efficacy across up to 350 adults at 40 US sites, aiming to eliminate manual insulin dosing and enhance outcomes with algorithm-driven automation.
- In April 2026, Modular Medical received FDA 510 (k) clearance for its Pivot tubeless insulin patch pump, featuring a two-part removable design and smartphone connectivity.
- In March 2026, MiniMed announced FDA clearance of its MiniMed Flex insulin pump, a compact, smartphone-controlled system with an adaptive SmartGuard algorithm for automated insulin adjustments.
- In February 2026, Insulet launched automated insulin delivery system in Middle East to transform diabetes care.
- In January 2026, Medtronic announced the USFDA 510(k) clearance of its MiniMed Go™ app featuring instinct sensor made by Abbott. This MiniMed Go™ smart multiple daily Injection (MDI) system seamlessly integrated the InPen™ smart insulin pen with the instinct sensor.
- In January 2026, Diabeloop and Sequel Med Tech entered into a partnership to integrate FDA-cleared DBLG2 into the twiist™ Automated Insulin Delivery System.
Scope of the Diabetes Drug Delivery Device Market Report
The “Diabetes Drug Delivery Devices Market: Industry Trends and Global Forecasts, till 2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market forecast, market outlook and future opportunities. The market research report features a detailed analysis of the key drivers and trends related to market.
The key objective of diabetes drug delivery devices market report is to provide a detailed market analysis in order to estimate the existing market size, market trends, market value, statistics and future opportunity for insulin delivery devices market during the forecast period. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the forecast period till 2030.
The market report also features sales forecasts for the overall market with a detailed market segmentation on the [A] type of device (pen-injectors, insulin pumps, conventional syringes and others), [B] route of administration (subcutaneous, intravenous and others), [C] diabetes type (type 1 diabetes and type 2 diabetes), [D] device usability (disposable and reusable) and [E] key geographies (North America, Europe, Asia Pacific and rest of the world).
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
Diabetes Drug Delivery Devices Market Report Coverage
Amongst other elements, the market report includes:
- An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector / autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin). In addition, the report present the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size and location of headquarters.
- A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage).
- An analysis of the partnerships that have been inked by the stakeholders in insulin delivery devices market, since 2015, covering technology integration agreements, product development agreements, distribution agreements, acquisitions, product commercialization agreements, supply agreements, licensing agreements, product development and commercialization agreements and other relevant types of deals.
- Elaborate profiles of the prominent players developing diabetes drug delivery devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
- A review of recent initiatives undertaken by big pharma players engaged in insulin delivery devices market. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues), based on their initiatives related to diabetes drug delivery devices.
Frequently Asked Questions
Question 1: What are diabetes drug delivery devices?
Answer: Diabetes drug delivery devices include novel diabetes treatment and management drug administering devices with minimal contamination and injuries risk.
Question 2: How big is the diabetes drug delivery devices market?
Answer: The diabetes drug delivery devices market size is estimated to be worth $18 billion in 2026.
Question 3: What is the projected market growth of the diabetes drug delivery devices market?
Answer: The diabetes drug delivery devices market is expected to grow at compounded annual growth rate (CAGR) of 14.1% during the forecast period 2026–2030.
Question 4: Who are the leading medical device companies in the diabetes drug delivery devices market?
Answer: Examples of key companies engaged in diabetes drug delivery devices market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Bigfoot Biomedical, Debiotech, Haselmeier, Medtronic, Novo Nordisk, Roche, SOOIL, and Ypsomed.
Question 5: Which devices are manufactured by the companies engaged in diabetes drug delivery devices market?
Answer: Medical device companies engaged in the diabetes drug delivery devices market provide insulin pumps, pen injectors / autoinjectors, jet injectors, intranasal drug delivery solutions and microneedle-based patches.
Question 6: How many products are currently marketed / under development by companies engaged in the diabetes drug delivery devices market?
Answer: More than 80 products are currently marketed / under development by players engaged in the diabetes drug delivery devices market.
Question 7: How many partnership deals have been inked by the stakeholders engaged in diabetes drug delivery devices market?
Answer: Since 2015, more than 60 partnership deals have been inked by the stakeholders engaged in diabetes drug delivery devices market, highlighting the consolidation efforts of players in the industry.
